Antiviral Drugs - Haiti | Statista Market Forecast

In 2024, the projected revenue in the Antiviral Drugs market is expected to reach US$4.69m in Haiti.
Looking ahead, a steady annual growth rate of 1.46% (CAGR 2024-2029) is anticipated, leading to a market volume of US$5.04m by 2029.
When compared to other countries, United States is forecasted to generate the highest revenue of US$30.64bn in 2024.
Despite the challenges of its healthcare system, Haiti has seen an increase in the demand for and availability of antiviral drugs to combat infectious diseases.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

The Antiviral Drugs market in Haiti is developing rapidly due to various factors.

Customer preferences: The demand for Antiviral Drugs in Haiti is driven by the increasing prevalence of viral infections. Haitians are becoming more aware of the importance of antiviral drugs in treating viral infections and are seeking treatment options. Additionally, the affordability of generic antiviral drugs has made them more accessible to the general population.

Trends in the market: The Antiviral Drugs market in Haiti is expected to grow as the government invests in improving healthcare infrastructure. The increasing prevalence of viral infections, such as HIV, hepatitis B and C, and influenza, is also driving the growth of the market. The market is also witnessing a shift towards more effective and targeted antiviral therapies.Local Special circumstances: Haiti is a low-income country with limited healthcare resources. The country is still recovering from the 2010 earthquake, which severely damaged the healthcare infrastructure. The lack of resources and infrastructure has resulted in limited access to healthcare services, including antiviral drugs. Additionally, the country has a high prevalence of infectious diseases, which further strains the healthcare system.

Underlying macroeconomic factors: The Haitian economy is heavily dependent on agriculture, which accounts for over 25% of the country's GDP. The country has a large informal economy, which limits the government's ability to collect taxes and invest in healthcare infrastructure. The country also faces political instability, which has hindered economic growth and development. These macroeconomic factors have a direct impact on the healthcare system and access to antiviral drugs.In conclusion, the Antiviral Drugs market in Haiti is developing rapidly due to increasing awareness of the importance of antiviral drugs, the affordability of generic drugs, and the increasing prevalence of viral infections. However, the lack of healthcare resources and infrastructure, high prevalence of infectious diseases, and political instability pose significant challenges to the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.